168 related articles for article (PubMed ID: 6451282)
1. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients.
Rose DP; Davis TE
Cancer Res; 1980 Nov; 40(11):4043-7. PubMed ID: 6451282
[TBL] [Abstract][Full Text] [Related]
2. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.
Jordan VC; Fritz NF; Tormey DC
Cancer Res; 1987 Jan; 47(2):624-30. PubMed ID: 3098415
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
[TBL] [Abstract][Full Text] [Related]
4. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
5. Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen.
Bhatavdekar JM; Shah NG; Patel DD; Karelia NH; Trivedi SN; Vora HH; Ghosh N; Giri DD; Balar DB
Neoplasma; 1992; 39(2):123-7. PubMed ID: 1528310
[TBL] [Abstract][Full Text] [Related]
6. Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer.
Bianco AR; De Placido S; Pagliarulo C; Fasano S; D'Istria M; De Sio L; Ricciardi I; Delrio G
Chemioterapia; 1985 Jun; 4(3):252-5. PubMed ID: 3839720
[TBL] [Abstract][Full Text] [Related]
7. Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients.
Rose DP; Chlebowski RT; Connolly JM; Jones LA; Wynder EL
Cancer Res; 1992 Oct; 52(19):5386-90. PubMed ID: 1394142
[TBL] [Abstract][Full Text] [Related]
8. [Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy].
Yasumura T; Oka T; Honjo H; Okada H
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2947-52. PubMed ID: 3140733
[TBL] [Abstract][Full Text] [Related]
9. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
Ravdin PM; Fritz NF; Tormey DC; Jordan VC
Cancer Res; 1988 Feb; 48(4):1026-9. PubMed ID: 3123050
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function.
Manni A; Pearson OH
Cancer Treat Rep; 1980; 64(6-7):779-85. PubMed ID: 6775808
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
13. Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer.
Blackburn AM; Wang DY; Bulbrook RD; Thomas BS; Kwa HG; Hoare SA; Rubens RD
Cancer Treat Rep; 1984 Dec; 68(12):1447-53. PubMed ID: 6239689
[TBL] [Abstract][Full Text] [Related]
14. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer.
Rose DP; Davis TE
Lancet; 1977 Jun; 1(8023):1174-6. PubMed ID: 68275
[TBL] [Abstract][Full Text] [Related]
15. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
[TBL] [Abstract][Full Text] [Related]
16. Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects.
Helgason S
Acta Obstet Gynecol Scand Suppl; 1982; 107():1-29. PubMed ID: 6282033
[TBL] [Abstract][Full Text] [Related]
17. Evidence of excessive androgen secretion by both the ovary and the adrenal in patients with idiopathic hirsutism.
Pugeat M; Forest MG; Nisula BC; Corniau J; De Peretti E; Tourniaire J
Obstet Gynecol; 1982 Jan; 59(1):46-51. PubMed ID: 6804896
[TBL] [Abstract][Full Text] [Related]
18. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Sverrisdottir A; Nystedt M; Johansson H; Fornander T
Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
[TBL] [Abstract][Full Text] [Related]
20. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]